Lupron (leuprolide) is typically prescribed for 2 to 5 years when used as part of breast cancer treatment, with 5 years being the most common standard duration. The exact length depends on your cancer’s stage, your risk of recurrence, and which other hormonal therapy you’re taking alongside it. In some higher-risk cases, treatment may extend beyond 5 years.
Why Duration Varies by Risk Level
Lupron is used specifically for premenopausal women with hormone receptor-positive breast cancer. It works by shutting down the ovaries’ production of estrogen, which fuels this type of cancer’s growth. The drug is almost always paired with another hormonal medication, either tamoxifen or an aromatase inhibitor like exemestane.
Five years of hormonal therapy remains the standard recommendation for early-stage breast cancer. But oncologists increasingly tailor the timeline based on individual risk. For women at intermediate risk of recurrence, around 7 years appears to be the optimal duration. For those with high-risk features, such as larger tumors, lymph node involvement, or aggressive tumor characteristics, hormonal therapy may continue for up to 10 years. The decision about whether Lupron specifically continues for that entire extended period, or whether you transition to a different approach, is made on a case-by-case basis.
A landmark set of clinical trials called SOFT and TEXT enrolled nearly 4,700 premenopausal women and studied 5 years of ovarian suppression (using drugs like Lupron) combined with either tamoxifen or an aromatase inhibitor. These trials established 5 years as the benchmark duration for ovarian suppression in this setting. Whether to extend beyond that, and how, remains an individualized decision your oncologist will revisit as you approach the end of your initial treatment window.
How Lupron Is Given
Lupron for breast cancer is delivered as an injection, not a daily pill. You’ll receive it on a regular schedule throughout your treatment period. The most common options are a monthly injection or a once-every-three-months depot injection. A six-month formulation also exists, though it’s less commonly discussed in the breast cancer context. Your oncologist will typically choose the schedule that fits best with your other treatment appointments and preferences.
The injections are intramuscular, usually given in the upper arm, thigh, or buttock at your oncologist’s office or infusion center. Because the drug is released slowly from the injection site over weeks, you don’t need to remember a daily dose.
What Lupron Is Paired With
Lupron alone isn’t a complete breast cancer treatment. It suppresses your ovaries, but you also need a medication that blocks or reduces estrogen’s effects throughout your body. The two main options are tamoxifen and an aromatase inhibitor.
Tamoxifen blocks estrogen from attaching to cancer cells and can be used whether or not your ovaries are suppressed. Aromatase inhibitors stop your body from making estrogen in other tissues (like fat), but they only work properly if your ovaries are fully shut down first. That’s why aromatase inhibitors always require Lupron or a similar drug in premenopausal women. The SOFT and TEXT trials showed that the combination of ovarian suppression plus an aromatase inhibitor provided the greatest benefit for women at higher risk of recurrence.
Both your Lupron and your companion medication generally run on the same timeline. If your oncologist recommends 5 years of hormonal therapy, you’ll typically receive Lupron injections for those same 5 years while also taking your oral medication daily.
Monitoring During Treatment
Your medical team will check blood work to confirm that Lupron is effectively suppressing your ovarian function. The key measurement is your estradiol level, a form of estrogen. For women taking an aromatase inhibitor, the target is very low, below roughly 2.7 pg/mL. For those on tamoxifen, the threshold is more lenient, generally below 21 pg/mL.
Up to a quarter of premenopausal women don’t achieve full ovarian suppression within the first 3 months of starting a drug like Lupron. For this reason, bloodwork should be checked before starting an aromatase inhibitor and at regular intervals afterward. If your estrogen levels aren’t dropping enough, your oncologist may adjust your treatment plan, potentially switching medications or adding interventions.
Bone Health Over Long Treatment
One of the most important considerations during years of Lupron therapy is bone density loss. By suppressing estrogen, Lupron induces a state similar to menopause, and estrogen plays a major role in keeping bones strong. This effect is compounded if you’re also taking an aromatase inhibitor, which further reduces estrogen throughout your body.
The American Society of Clinical Oncology considers women who experience treatment-related premature menopause to be at high risk for osteoporosis. For these patients, an initial bone density scan (DEXA scan) followed by annual assessments is recommended. Your oncologist may also suggest calcium and vitamin D supplements or, if bone loss becomes significant, a bone-strengthening medication. Staying physically active with weight-bearing exercise is one of the most effective things you can do to protect your bones during treatment.
What Happens When Treatment Ends
When you and your oncologist decide it’s time to stop Lupron, you simply discontinue the injections. Ovarian function typically returns afterward in women who are still young enough for their ovaries to recover, though the timeline varies. Some women see their periods return within a few months, while for others it takes longer, especially if they were closer to natural menopause when treatment began or if prior chemotherapy also affected their ovaries.
The transition off treatment is gradual, not abrupt. Your oncologist will continue to monitor you with follow-up appointments and may check hormone levels to understand whether your ovaries have resumed functioning. If ovarian function does return, your care team will factor that into your ongoing surveillance plan, since estrogen production resuming means the hormonal environment that originally supported the cancer is back in play.